ABSTRACT The use of both bilateral prophylactic mastectomy and contralateral prophylactic mastectomy (CPM) has increased significantly during the last decade. Various risk models have been developed to identify patients at increased risk for breast cancer. The indications for bilateral prophylactic mastectomy for patients without a diagnosis of breast cancer include high risk from mutation in BRCA or other breast cancer predisposition gene, very strong family history with no identifiable mutation, and high risk based on breast histology. Additionally, the use of CPM has more than doubled in the last decade, and this increase is noted among all stages of breast cancer, even in patients with ductal carcinoma in situ (stage 0). The risk of contralateral breast cancer often is overestimated by both patients and physicians. Nevertheless, specific risk factors are associated with an increased risk of contralateral breast cancer, including BRCA or other genetic mutation, young age at diagnosis, lobular histology, family history, and prior chest wall irradiation. Although CPM reduces the incidence of contralateral breast cancer, the effect on disease-free survival and, more importantly, overall survival is questionable and underscored by the fact that the reason most patients choose CPM is to achieve ''peace of mind.'' Newer and effective reconstructive options have made the procedure more attractive. This panel addresses the indications and rationale for bilateral prophylactic mastectomy and CPM, the decision-making process by patients, and ethical considerations. Changes in the physician-patient relationship during the past few decades have altered the approach, and ethical considerations are paramount in addressing these issues.
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The use of both bilateral prophylactic mastectomy and CPM has increased significantly during the last decade. Additionally, the use of CPM has more than doubled in the last decade. The risk of contralateral breast cancer (CBC) often is overestimated by both patients and physicians. Although CPM reduces the incidence of CBC, the effect on disease-free survival (DFS) and, more importantly, overall survival (OS) is questionable and underscored by the fact that the reason most patients choose CPM is to achieve ''peace of mind.'' This panel addresses the indications and rationale for CPM, the decision-making process by patients, and ethical considerations.
IS THERE A SURVIVAL BENEFIT TO SURGERY?
For patients interested in CPM, several end points need to be considered. The first end point is an assessment of the risk for CBC to determine the absolute potential decrement in CBC risk with CPM. The following factors contribute to the risk of a second breast cancer: BRCA mutation status, family history (regardless of BRCA), age at diagnosis, hormone receptor status, and possibility of adjuvant endocrine therapy. [1] [2] [3] [4] [5] A deleterious BRCA1 or BRCA2 mutation, family history of breast cancer (particularly firstdegree relatives), younger age at diagnosis (even without a family history), and hormone receptor-negative tumors all are associated with an increased risk for CBC.
Dynamic associations among these factors have an impact on long-term CBC risk. Even among BRCA mutation carriers, the risk of CBC varies based on the age of the initial breast cancer diagnosis. 6 Similarly, the number and age of affected family members have an impact on the CBC risk for a BRCA mutation carrier. 3 Among women who are not BRCA mutation carriers, age-based risk varies with family history. 1 These associations create additional complexity in attempts to determine any given woman's risk of CBC. To date, no one single model exists that comprehensively accounts for all these risk elements and considers their interdependent influence on CBC risk. Increasing Tyrer-Cuzick or Claus models for risk assessment provide more accurate and comprehensive information for physicians and patients. Additionally, increasing referrals to genetic counselors provide significant improvement in risk assessment and information regarding hereditary disease.
A second consideration in the counseling of patients considering CPM is the impact of the operation on DFS related to recurrence of the index breast cancer. The field is challenged by limited data, and studies rely heavily on population-level analyses and statistical modeling. However, these data do suggest a modest association between CPM and DFS in small subsets of women, typically those with early-stage disease that is hormone receptor-negative diagnosed at a young age. [7] [8] [9] For the majority of breast cancer patients, no clear data exist that demonstrate an association between CPM and DFS and speak to the unique combination of events that need to be present to affect DFS outcomes, namely, a relatively low risk of dying due to the index event coupled with a relatively high risk of CBC and few, if any, other comorbid conditions that would contribute to early mortality. This combination of findings is relatively uncommon among the breast cancer population and deserves consideration in assisting patients in their decision for CPM.
Finally, data are even scarcer and less compelling in demonstrating the benefit of CPM and OS. Although Herrinton et al. 10 showed an improvement in all-cause mortality associated with CPM, their data need to be taken with caution because their analysis also demonstrated improvement in mortality from causes other than breast cancer as a result of CPM. Because the only potential mechanism whereby CPM may improve survival is reduction of CBC, a finding of CPM improvement in survival not associated with breast cancer leads to significant concerns of bias. More compelling data from Portschy modeling OS outcomes from CPM show no meaningful improvement. 9 This lack of OS benefit from CPM is because most CBCs are detected early, prove to be curable, and thus have no impact on OS.
NAVIGATING SURGICAL TREATMENT DECISIONS WITH PATIENTS
Surgeons are surprised by the surge of patient interest and desire for CPM with reconstruction. Only about 5 % of women with breast cancer received CPM in 2006, representing about 10-15 % of the mastectomies performed that year. 11 The most recent data suggest that CPM rates have increased to as much as 25 % of patients with newly diagnosed disease, representing up to half of women undergoing mastectomy. Nearly 90 % of patients who have CPM undergo reconstruction. Currently, most women who receive CPM have no elevated risk of a second breast cancer. 12 Thus, CPM provides no benefit of DFS. 13 The reasons for the increased rates of CPM are largely due to patient heightened awareness and desire for more extensive surgery. Dramatic, highly publicized stories of media celebrities undergoing ''life-saving'' CPM created a powerful image that resonated with patients. These stories conflated scenarios of women with marked elevated risk of a second breast cancer whose CPM conferred a documented benefit of risk reduction, with breast cancer patients at an average risk of a second breast cancer showing no benefit of DFS. Patients are more aware of the CPM from media reports but also from neighbors, friends, colleagues, or family members who have undergone CPM and are proponents of the procedure.
Powerful intuitive judgment factors, heuristics, and counterfactual thinking fuel the desire for more extensive treatment. Aversion to uncertainty and the desire for greater peace of mind are endorsed by virtually all women who undergo CPM. These women desire to move beyond the threat of the diagnosis as completely and quickly as possible. Another powerful driver is anticipated regret: we make decisions at the moment to minimize future regret. Many patients convey this counterfactual thinking by saying, ''I want to do everything I can now because if I get a recurrence I feel that I did what I could.'' A fundamental problem with anticipated regret is that it focuses on the total threat of recurrence rather than the net benefit of the different treatment options. Furthermore, psychology research has confirmed we are not good at predicting our reactions to future events. Heuristics and counterfactual thinking are cloaked in the abyss of the subconscious and thus are difficult to address. A paradox increasingly recognized is that patient satisfaction with surgical treatment decision making is very high, but their knowledge about the tradeoffs between the different treatment options is extremely low.
14 This paradox underscores that patient deliberation over numbers is not a primary determinant of preference for treatment.
The dominance of intuition over deliberation in patient preferences for treatment poses major challenges for surgeons. 15 One important goal is to focus the patient's attention on the net benefit of treatment and away from the total threat of the disease. Surgeons need strategies to focus patient attention on the lack of benefit from CPM in terms of DFS. The immediate intuitive reaction of patients to the management plan is not the same as long-term quality of life. Larger breast surgery is back on the radar screen. Research is needed to examine how patient, surgeon, and system factors influence the use of expanding treatment options for women.
THE CHOICE FOR CONTRALATERAL PROPHYLACTIC MASTECTOMY: AUTONOMY AND ETHICS
The ''epidemic'' of requests for CPM often comes from women without genetic or other risk factors for cancer. Clinicians have used CPM for both small invasive cancers and DCIS.
Case Report
A 39-year-old woman has a 1.7-cm invasive lobular breast carcinoma. Her surgeon discusses the options of breast conservation versus mastectomy. The patient requests a mastectomy with CPM because of concerns with recurrence. Despite the surgeon's outlining of increased risks and longer operative times, if the patient wants CPM, most surgeons will provide it, and most insurance companies will pay for it.
Would This Situation Have Been Different 50 Years Ago?
A 39-year-old woman presented with a 2-cm breast lump in 1970. The surgeon likely encouraged her to have a ''one-step procedure'' (i.e., a biopsy under general anesthesia and, if the lump is cancerous, a radical mastectomy). This approach eliminated any discussion of ''controversial'' less aggressive procedures. Doctors and patients had long-standing relationships and often shared a common value system. As the medical authority, the doctor made the decisions, and medical benefit was equated with patient benefit. Patients were vulnerable and passive.
The evidence of paternalism is clear. The diagnosis of cancer often was not discussed with patients. A study presented in JAMA in 1961 reported interviews with physicians regarding what they tell patients about diagnoses, and 88 % of the physicians stated that they generally did not tell a patient a diagnosis of cancer. 16 In the past several decades, many changes have occurred in the ethos of medical practice. The concept that doctors always know best has been challenged. Physicians have come to accept that what is medically beneficial might not always be best for a patient. The question ''what can be done?'' often has been replaced with ''what should be done?'' To answer this latter question when doctors and patients less frequently shared a common value system, patient input became essential.
Respect for patient autonomy became the new paradigm for the doctor-patient relationship. Patients needed information to participate in decisions, and ''shared decision making'' became widely accepted. Evidence for this change is clear. Novack et al. 17 in 1979, conducted the same survey in the same hospital as Oken 16 had studied 16 years earlier. But this time, 98 % of the physicians reported that their ''general policy is to tell patients a cancer diagnosis.'' During the 16 years, significant changes occurred in breast cancer treatment. Radical mastectomy lost favor. Randomized controlled trials became the standard for evidence. Activism in breast cancer became important. Laws were passed mandating the discussion of options. A 1979 Massachusetts law required surgeons to advise each breast cancer patient of all alternatives to mastectomy. By 1990, 16 states had similar laws. All required presentation of alternatives so that patients could make the choice of treatment for themselves.
Consider CPM and patient benefit. How should physicians weigh improved quality of life relative to whether CPM benefits the patient? We are seeing a paradigm shift. Medical progress is no longer determined purely by improvement in outcome. Benefit previously defined as increased longevity or decreased morbidity and mortality is now defined relative to the patient's values.
Currently, respect for patient autonomy is central in medical ethics. However, this principle must be balanced against nonmaleficence (avoidance of doing harm). If a patient with no risk factors for cancer were to request bilateral prophylactic mastectomy, many surgeons would find this request unacceptable.
A central controversy centers on this question: Are we seeing the appropriate extension of respect for patient autonomy in cooperation with all requests for CPM? Or has the pendulum swung too far such that physicians no longer have input on what will benefit patients?
Patient choice is critical, and respect for patient autonomy is essential for ethical practice. However, respecting autonomy does not require acceding to every patient request. Surgeons genuinely care that patients make informed decisions and should focus on continuing to help patients understand the real clinical and psychological benefits of CPM. These efforts will ensure that true ''shared decision making'' occurs.
BEYOND BRCA1 AND BRCA2
Mutations in BRCA1 and BRCA2 account for the majority of familial breast cancer cases with an identifiable cause. The invention of massive parallel sequencing and the subsequent commercialization of multi-gene panel tests have greatly expanded the list of breast cancer predisposition genes but has been able to explain only an additional 5-7 % of apparent genetic high risk families. 18, 19 When a sequence variant is identified on a panel test, the first task is to determine whether that variant increases cancer risk or not. We usually rely on the company performing the test to do this for us. This is the major source of variability in test results reported by different providers. It is important to recognize that some of the genes included on panel tests have not been convincingly linked to breast cancer and a 20-40 % chance exists that the test will identify a sequence variant that simply cannot be classified as deleterious or that is not based on existing information. Some approaches to avoiding interpretation difficulties include testing only families with multiple cases of early-onset breast cancer, testing first the relative with the greatest mutation probability, and restricting the test to genes for which published management guidelines exist (BRCA1, BRCA2, TP53, CDH1, STK11 and PTEN). 20 Once a deleterious mutation has been identified, the next step is to estimate the cancer risk for the specific family in question. Apart from BRCA1 and BRCA2, the genes most commonly identified on panel tests are CHEK2, PALB2, and ATM. These genes have traditionally been classified as moderate penetrance genes, and in most families, this is likely the case. No cancer predisposition gene acts in isolation, however. Each can be made more or less virulent depending on the genetic background of the family. For example, one study that genotyped CHEK2 for four founder mutations in 7494 BRCA1 mutation-negative patients with breast cancer and 4346 control women estimated the lifetime breast cancer risk for truncating mutations at 20 % for a woman with no affected relative, 28 % for a woman with one affected second-degree relative, 34 % for a woman with one first-degree relative, and 44 % for a woman with both first-and second-degree relatives. 21 Similarly, most missense mutations in ATM are unlikely to increase breast cancer risk significantly, but certain rare mutations have been associated with up to a 60 % lifetime risk in some families. 22, 23 The situation is similar for PALB2, with families being identified increasingly with breast cancer risk similar to that for high-risk BRCA2 families. When confronted with a deleterious mutation in any gene, including BRCA1 or BRCA2, the clinician must first go back to the extended pedigree to estimate the familyspecific penetrance. Lifetime breast cancer risk in some families will be high enough to warrant risk-reducing mastectomy, but for others, less invasive alternatives, such as enhanced surveillance, may be more reasonable.
CPM AND IMPLICATIONS FOR RECONSTRUCTION
Although a woman's choice to undergo CPM clearly is multifactorial, reconstruction is an important consideration and a potential influence. Postmastectomy reconstruction may be performed using either breast implants or a woman's own tissue (autologous reconstruction). Although both approaches create a breast mound, the long-term outcomes show subtle but significant differences. These differences are most pronounced among women undergoing unilateral mastectomy and reconstruction. Specifically, unilateral implant reconstruction generally fails to ''match'' fully the contralateral breast without a bra. Studies of patient-reported outcomes suggest that over time, this asymmetry actually worsens as the contralateral natural breast becomes more ptotic and changes in size with patient weight gain or loss. 24 In contradistinction, unilateral autologous reconstruction creates a breast that more closely matches the contralateral breast and remains more stable over time. 25 In the United States, breast reconstruction rates are steadily rising, 26 with the majority of this increase attributable to an upsurge in implant reconstruction. 27 This is perhaps puzzlingly given the superior long-term outcomes associated with autologous reconstruction. Limited access to autologous reconstruction may be a factor. Autologous tissue transfer has evolved from pedicled flaps to more technically challenging microvascular perforator flaps generally performed in specialized higher-volume centers. The request of a woman with breast cancer for autologous reconstruction may thus mean delays in treatment or surgery outside her local community.
At this point, the woman's decision to undergo CPM intersects with the approach to reconstruction. Women generally want their breasts to match, 28 and when offered only implant reconstruction, some will choose bilateral mastectomies as a means to achieve better symmetry. Although psychological factors, individual perceptions of risk, and societal trends are likely the central influences on a woman's decision to pursue CPM, expectations for reconstruction are also a component of the decision-making matrix. Few patients would request removal of their contralateral breast purely for aesthetic reasons, but many will factor this in. The solution is more uniform access to autologous reconstruction. 29 Although not all women will be candidates for autologous reconstruction or willing to accept longer surgery and donor-site scars, it is nevertheless important that all patients have access to the full spectrum of reconstructive techniques. When only implant reconstruction is offered, removal of the contralateral healthy breast may otherwise seem to be the most appropriate decision.
